 |
Prodrug strategies have traditionally been used to address ADMET liabilities of
marketed compounds or as tools in late-stage problem solving for drug development
candidates. However, prodrugs are now increasingly being integrated into early
drug discovery as a means of expanding the chemical space of drugable molecules.
Two years ago, the Prodrug Focus Group was formed with the following section
affiliations; Physical Pharmacy and Biopharmaceutics (PPB), Drug Design and
Discovery (DDD), and Pharmacokinetics, Pharmacodynamics and Drug Metabolism (PPDM).
The goals of the Prodrug Focus Group are to expand drug delivery knowledge of
prodrug possibilities through education, impact the direction of prodrug research
through long-range programming, encourage interdisciplinary collaborations in
prodrug research, encourage innovative use of new technologies to solve prodrug
problems, and provide a common prodrug forum for universities, industry, and
government.
To achieve these goals, we will continue to build interdisciplinary programming
between PPB, DDD, and PPDM sections, develop a young and sustainable leadership
pool for the Prodrug Focus Group, plan an intermediate-range program so researchers
can anticipate future forums for innovative research, provide an inclusive
environment for programming ideas into workshops, symposia, roundtables, and short
courses; and foster interdisciplinary collaborations and research that, in turn,
would advance the discipline, health care, consumer interests, and AAPS programming
quality. To achieve this, the Prodrug Focus Group will serve as a forum for prodrug
scientists/enthusiasts in many areas including metabolism; drug delivery and
targeting; chemical synthesis; molecular biology; biotechnology; drug safety;
clinical trial testing; as well as drug approval and regulation.
Goals
The goals of the Prodrug Focus Group are to:
- expand drug delivery knowledge of prodrug possibilities through education
- impact the direction of prodrug research through long-range programming
- encourage interdisciplinary collaborations in prodrug research
- encourage innovative use of new technologies to solve prodrug problems
- provide a common prodrug forum for universities, industry, and government
To achieve these goals we will:
- develop interdisciplinary programming between PPB, DDD, & PPDM
- develop a young and sustainable leadership pool for the Prodrug Focus Group
- plan an intermediate-range program so researchers can anticipate future forums for innovative research
- provide an inclusive environment for programming ideas into workshops, symposia, roundtables, and short courses
- foster interdisciplinary collaborations and research that, in turn, would advance the discipline, health care, consumer interests, and AAPS programming quality. Our working assumption is that by providing such a forum for prodrug designers in the areas of:
- Metabolism
- Drug Delivery and Targeting
- Chemical Synthesis
- Molecular Biology
- Biotechnology
- Drug Safety
- Clinical Trial Testing
- Drug Approval and Regulation
Prodrugs will be used more often and sooner as a means of overcoming the physical/chemical liabilities of active therapeutic agents so that more innovative therapies will reach the market place.
Upcoming Programming
Sunrise Sessions
- Accurate Prediction of Metabolic DDI - from Preclinical Discovery to Clinical Development
Time: Wednesday, November 19, 2008 from 07:00 am - 08:15 am
- Tumor Imaging and Targeted Drug Delivery
Time: Wednesday, November 19, 2008 from 07:00 am - 08:15 am
- Rational Drug and Prodrug Design Via Computational Modeling
Time: Tuesday, November 18, 2008 from 07:00 am - 08:15 am
- PK/PD of Biologics: from Discovery to Successful Development
Time: Tuesday, November 18, 2008 from 07:00 am - 08:15 am
Roundtables
- The World Within and Beyond P-gp: Do we Underestimate or Overestimate P-gp?
Time: Wednesday, November 19, 2008 from 09:00 am - 11:00 am
- Prodrug approaches for organ specific targeted therapy
Time: Thursday, November 20, 2008 from 09:00 am - 11:00 am
- Transporters as Prodrug Carriers for Oral Drug Delivery
Time: Wednesday, November 19, 2008 from 02:00 pm - 04:00 pm
- Effective Interactions from Pre-IND to IND and Beyond: “getting your Ducks in the Row” with the FDA
Time: Thursday, November 20, 2008 from 09:00 am - 11:00 am
Past Programming
Prodrug Approaches for Site-Specific Cellular Targets Roundtable
November 15, 2007
Tumor-activated Prodrug and Tumor-targeting Technologies: ADEPT, GDEPT and PDEPT to Increase Drug Efficacy and Reduce Drug Toxicity Roundtable
November 14, 2007
Solving ADMET Problems with Prodrug, Soft-Drug & Co-Drugs Roundtable, November 2, 2006
Panel members: Howard Ando, Paul Erhardt, Peter Crooks
Moderators: Howard Ando and Tycho Heimbach
Strategies & Technologies for Transdermal and Ocular Drug Delivery Roundtable, November 1, 2006
Panel members: Bo Michniak-Kohn, Diane Tang-Liu, Ken Sloan
Moderators: Jarkko Rautio and Ken Sloan
Facilitating Parent-Prodrug R&D and Regulatory Approval Roundtable, October 30, 2006
Panel members: Yuanchao Zhang, Mary Beth Wire, Reza Oliyai
Moderators: Tycho Heimbach and Paul Erhardt
JOIN THE PRODRUG FOCUS GROUP
To join the Prodrug Focus Group, click here.
Back To Top
|
|
|
|
|
|
|
Steering Committee Member
Dr. Paul W. Erhardt
University of Toledo College of Pharmacy
Toledo, OH UNITED STATES |
|
|